Identification

Name
Vancomycin
Accession Number
DB00512  (APRD01287, EXPT03217)
Type
Small Molecule
Groups
Approved
Description

Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.

As of January 29 2018, CutisPharma's Firvanq is the only FDA approved vancomycin oral liquid treatment option available for the the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains [LP1196]. Such an oral liquid formulation is expected to make Clostridium difficile associated diarrhea therapy more accessible in comparison to previously available specialty compounding products [LP1196].

Structure
Thumb
Synonyms
  • (1S,2R,18R,22S,25R,28R,40S)-22-(2-amino-2-oxoethyl)-48-[2-O-(3-amino-2,3,6-trideoxy-3-methyl-α-L-lyxo-hexopyranosyl)-β-D-glucopyranosyloxy]-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(N-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid
  • (2.2Sp,3.5Sa,2.6Sp)-O4.2,C3.4:C5.4,O4.6:C3.5,C2.7-tricyclo[N-methyl-D-leucyl-3-chloro-(R)-β-hydroxy-D-tyrosyl-L-asparaginyl-D-2-(4-{[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl-α-L-lyxo-hexopyranosyl)-β-D-glucopyranosyl]oxy}phenyl)glycyl-D-2-(4-hydroxyphenyl)glycyl-3-chloro-(R)-β-hydroxy-L-tyrosyl-L-2-(3,5-dihydroxyphenyl)glycine]
  • Vancomicina
  • Vancomycine
  • Vancomycinum
Product Ingredients
IngredientUNIICASInChI Key
Vancomycin hydrochloride71WO621TJD1404-93-9LCTORFDMHNKUSG-XTTLPDOESA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
FirvanqKitOralCutis Pharma, Inc.2018-01-26Not applicableUs
FirvanqKitOralCutis Pharma, Inc.2018-01-26Not applicableUs
FirvanqKitOralCutis Pharma, Inc.2018-01-26Not applicableUs
FirvanqKitOralCutis Pharma, Inc.2018-01-26Not applicableUs
Sterile Vancomycin HCl 5.0gm/vialPowder, for solution5 gIntravenousLyphomed, Division Of Fujisawa Canada Inc.1992-12-311996-09-10Canada
Sterile Vancomycin HCl USP 1.0gm/vialPowder, for solution1 gIntravenousLyphomed, Division Of Fujisawa Canada Inc.1992-12-311996-09-10Canada
Sterile Vancomycin HCl USP 500mg/vialPowder, for solution500 mgIntravenousLyphomed, Division Of Fujisawa Canada Inc.1992-12-311996-09-10Canada
Sterile Vancomycin Hydrochloride, USPPowder, for solution1 gIntravenousPartners Health Care, Inc.1987-12-312008-02-15Canada
Sterile Vancomycin Hydrochloride, USPPowder, for solution500 mgIntravenousPartners Health Care, Inc.1959-12-312008-02-15Canada
VancocinCapsule250 mgOralMerus Labs International Inc.1989-12-31Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Jamp-vancomycinCapsule250 mgOralJamp Pharma Corporation2014-03-26Not applicableCanada
Jamp-vancomycinPowder, for solution500 mgIntravenousJamp Pharma Corporation2014-09-22Not applicableCanada
Jamp-vancomycinPowder, for solution5 gIntravenousJamp Pharma Corporation2014-09-22Not applicableCanada
Jamp-vancomycinCapsule125 mgOralJamp Pharma Corporation2014-03-26Not applicableCanada
Jamp-vancomycinPowder, for solution1 gIntravenousJamp Pharma Corporation2014-09-22Not applicableCanada
Jamp-vancomycinPowder, for solution10 gIntravenousJamp Pharma Corporation2014-06-06Not applicableCanada
Mylan-vancomycin Hydrochloride for Injection, USPPowder, for solution500 mgIntravenousMylan PharmaceuticalsNot applicableNot applicableCanada
Mylan-vancomycin Hydrochloride for Injection, USPPowder, for solution5 gIntravenousMylan PharmaceuticalsNot applicableNot applicableCanada
Mylan-vancomycin Hydrochloride for Injection, USPPowder, for solution1 gIntravenousMylan PharmaceuticalsNot applicableNot applicableCanada
Mylan-vancomycin Hydrochloride for Injection, USPPowder, for solution10 gIntravenousMylan PharmaceuticalsNot applicableNot applicableCanada
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Vancomycin HClVancomycin hydrochloride (4.2 mg/mL)Injection, solutionIntravenousCantrell Drug Company2013-05-01Not applicableUs
Vancomycin HClVancomycin hydrochloride (6 mg/mL)Injection, solutionIntravenousCantrell Drug Company2012-05-25Not applicableUs
Vancomycin HClVancomycin hydrochloride (5 mg/mL)Injection, solutionIntravenousCantrell Drug Company2012-05-25Not applicableUs
International/Other Brands
COVANC (Nucleus) / Vancocin / Vancoled
Categories
UNII
6Q205EH1VU
CAS number
1404-90-6
Weight
Average: 1449.254
Monoisotopic: 1447.430199787
Chemical Formula
C66H75Cl2N9O24
InChI Key
MYPYJXKWCTUITO-LYRMYLQWSA-N
InChI
InChI=1S/C66H75Cl2N9O24/c1-23(2)12-34(71-5)58(88)76-49-51(83)26-7-10-38(32(67)14-26)97-40-16-28-17-41(55(40)101-65-56(54(86)53(85)42(22-78)99-65)100-44-21-66(4,70)57(87)24(3)96-44)98-39-11-8-27(15-33(39)68)52(84)50-63(93)75-48(64(94)95)31-18-29(79)19-37(81)45(31)30-13-25(6-9-36(30)80)46(60(90)77-50)74-61(91)47(28)73-59(89)35(20-43(69)82)72-62(49)92/h6-11,13-19,23-24,34-35,42,44,46-54,56-57,65,71,78-81,83-87H,12,20-22,70H2,1-5H3,(H2,69,82)(H,72,92)(H,73,89)(H,74,91)(H,75,93)(H,76,88)(H,77,90)(H,94,95)/t24-,34+,35-,42+,44-,46+,47+,48-,49+,50-,51+,52+,53+,54-,56+,57+,65-,66-/m0/s1
IUPAC Name
(1S,2R,18R,19R,22S,25R,28R,40S)-48-{[(2S,3R,4S,5S,6R)-3-{[(2S,4S,5S,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy}-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-22-(carbamoylmethyl)-5,47-dichloro-2,18,32,35,37-pentahydroxy-19-[(2R)-4-methyl-2-(methylamino)pentanamido]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2³,⁶.2¹⁴,¹⁷.1⁸,¹².1²⁹,³³.0¹⁰,²⁵.0³⁴,³⁹]pentaconta-3,5,8,10,12(48),14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid
SMILES
CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)C2=CC=C(OC3=C(O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O[C@H]4C[C@](C)(N)[C@H](O)[C@H](C)O4)C4=CC(=C3)[C@@H](NC(=O)[C@H](CC(N)=O)NC1=O)C(=O)N[C@@H]1C3=CC(=C(O)C=C3)C3=C(O)C=C(O)C=C3[C@H](NC(=O)[C@@H](NC1=O)[C@H](O)C1=CC(Cl)=C(O4)C=C1)C(O)=O)C(Cl)=C2

Pharmacology

Indication

A variety of dosage forms (for example, oral, injections, etc.) exist for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci [Label].

Additionally, a unique FDA approved oral liquid treatment is also available and indicated for the treatment of Clostridium difficile associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains [9].

Associated Conditions
Pharmacodynamics

Vancomycin is a branched tricyclic glycosylated nonribosomal peptide produced by the fermentation of the Actinobacteria species Amycolatopsis orientalis (formerly Nocardia orientalis) [10]. It is often reserved as the "drug of last resort", used only after treatment with other antibiotics has failed. Vancomycin has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections: Listeria monocytogenes, Streptococcus pyogenes, Streptococcus pneumoniae (including penicillin-resistant strains), Streptococcus agalactiae, Actinomyces species, and Lactobacillus species. The combination of vancomycin and an aminoglycoside acts synergistically in vitro against many strains of Staphylococcus aureus, Streptococcus bovis, enterococci, and the viridans group streptococci [Label].

Mechanism of action

The bactericidal action of vancomycin results primarily from inhibition of cell-wall biosynthesis. Specifically, vancomycin prevents incorporation of N-acetylmuramic acid (NAM)- and N-acetylglucosamine (NAG)-peptide subunits from being incorporated into the peptidoglycan matrix; which forms the major structural component of Gram-positive cell walls. The large hydrophilic molecule is able to form hydrogen bond interactions with the terminal D-alanyl-D-alanine moieties of the NAM/NAG-peptides. Normally this is a five-point interaction. This binding of vancomycin to the D-Ala-D-Ala prevents the incorporation of the NAM/NAG-peptide subunits into the peptidoglycan matrix. In addition, vancomycin alters bacterial-cell-membrane permeability and RNA synthesis. There is no cross-resistance between vancomycin and other antibiotics. Vancomycin is not active in vitro against gram-negative bacilli, mycobacteria, or fungi. [10]

TargetActionsOrganism
AD-Ala-D-Ala moiety of NAM/NAG peptide subunits of peptidoglycan
ligand
Gram-positive bacteria
Absorption

Poorly absorbed from gastrointestinal tract, however systemic absorption (up to 60%) may occur following intraperitoneal administration [Label].

Volume of distribution

The volume of distribution, as discussed in the literature, varies between 0.4-1 L/kg [6].

Protein binding

Approximately 50% serum protein bound [7].

Metabolism

Since almost 75-80% of the drug is excreted unchanged in the urine after the first 24 hours following administration, there is seemingly no apparent metabolism of the drug [Label]. The concentration of vancomycin in the liver tissue and bile 24 hours after administration has also been reported at or below detection limits as well [8].

Route of elimination

In the first 24 hours, about 75-80% of an administered dose of vancomycin is excreted in urine by glomerular filtration [Label].

Half life

Half-life in normal renal patients is approximately 6 hours (range 4 to 11 hours). In anephric patients, the average half-life of elimination is 7.5 days [Label].

Clearance

The mean plasma clearance of vancomycin is about 0.058 L/kg/h [Label].

Toxicity

The oral LD50 in mice is 5000 mg/kg. The median lethal intravenous dose is 319 mg/kg in rats and 400 mg/kg in mice. [Label]

Conversely, the most common adverse effects associated with vancomycin appear to be nausea, abdominal pain, and hypokalemia [Label]. In particular, incidences of hypokalemia, urinary tracy infection, peripheral edema, insomnia, constipation, anemia, depression, vomiting, and hypotension are higher among subjects >65 years of than in those that are 65 years old or younger [Label].

Additionally, nephrotoxicity involving reports of renal failure, renal impairment, elevated blood creatinine, and others has also occurred with vancomycin therapy during studies, and can occur during or after completion of a course of therapy [Label]. Risk of such nephrotoxicity is increased in patients greater than 65 years of age [Label].

Ototoxicity has also occurred in patients receiving vancomycin treatment, and it can be transient or permanent. This effect has been reported primarily in patients who have been given excessive intravenous doses, who have kidney dysfunction, who have an underlying hearing loss, or who are receiving concomitant therapy with another ototoxic agent like an aminoglycoside [Label]. Potentially related adverse effects like vertigo, dizziness, and tinnitus have also been reported [Label].

Neutropenia, often beginning one week or more after onset of intravenous vancomycin therapy or after a total dose of more than 25 mg has been observed for several dozen patients as well. This neutropenia however, appears to be promptly reversible when the vancomycin treatment is discontinued. Alternatively, thrombocytopenia has also been reported [Label].

Additionally, a condition has been reported that is described as being similar to IV-induced symptoms involving symptoms consistent with anaphylactoid reactions, including hypotension, wheezing, dyspnea, urticaria, pruritus, flushing of the upper body (in what is known as the so-called 'Red Man Syndrome'), pain and muscle spasm of the chest and back. Although on average such reactions usually resolve within 20 minutes, they are just as likely to persist for hours [Label].

In a controlled clinical study, the potential ototoxic and nephrotoxic effects of vancomycin on infants were assessed when the drug was given intravenously to pregnant women for serious staphylococcal infections complicating intravenous drug abuse. The results obtained demonstrated that vancomycin was found in cord blood but that no sensorineural hearing loss or nephrotoxicity attributable to vancomycin was noted. Ultimately however, because the number of subjects treated in this study was limited and vancomycin was administered only in the second and third trimesters, it is not formally known whether vancomycin causes fetal harm. Subsequently, vancomycin should be given to a pregnant woman only if clearly needed [Label].

Although it is known that vancomycin is excreted in human milk based on information obtained from the intravenous administration of the medication, it is not known if vancomycin is excreted into human milk after oral administration. However, because of the overall potential for adverse events, caution must be exercised when vancomycin is given to a nursing woman and a decision must be made whether to discontinue nursing or discontinue the drug, taking into consideration the importance of the drug to the mother [Label].

The safety and effectiveness in pediatric patients have not been formally established [Label].

Patients older than 65 years of age may take longer to respond to therapy compared to patients aged 65 year or younger. Vancomycin treatment in patients aged older than 65 years subsequently should not be discontinued or switched to an alternative treatment prematurely [Label].

Furthermore, clinical studies have demonstrated that geriatric patients are at increased risk of developing nephrotoxicity following treatment with oral vancomycin, which can occur during or after completion of therapy. In patients aged older than 65 years, including those with normal renal function prior to treatment, renal function should be monitored during and following treatment with vancomycin to detect any potential vancomycin induced nephrotoxicity [Label].

Affected organisms
  • Enteric bacteria and other eubacteria
  • Corynebacterium diphtheriae
  • Treponema pallidum
  • Streptococcus pyogenes
  • Chlamydia pneumoniae
  • Chlamydia trachomatis
  • Mycoplasma pneumoniae
  • Neisseria gonorrhoeae
  • Legionella pneumophila
  • Bordetella pertussis
  • Chlamydia psittaci
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when Vancomycin is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when 3,4-Methylenedioxyamphetamine is combined with Vancomycin.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Vancomycin.Experimental, Illicit
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Vancomycin.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when Vancomycin is combined with 5-methoxy-N,N-dimethyltryptamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Vancomycin.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Vancomycin.Experimental
AceclofenacAceclofenac may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Investigational
AcemetacinAcemetacin may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Experimental, Investigational
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Vancomycin.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Vancomycin.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Vancomycin.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Vancomycin.Approved
Acetylglycinamide chloral hydrateThe risk or severity of adverse effects can be increased when Acetylglycinamide chloral hydrate is combined with Vancomycin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Vet Approved
AdinazolamThe risk or severity of adverse effects can be increased when Adinazolam is combined with Vancomycin.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with Vancomycin.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Vancomycin.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Vancomycin is combined with Alaproclate.Experimental
AlclofenacAlclofenac may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Withdrawn
AlcuroniumThe therapeutic efficacy of Alcuronium can be increased when used in combination with Vancomycin.Experimental
Alendronic acidThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Vancomycin is combined with Alendronic acid.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Vancomycin.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Vancomycin.Approved, Illicit
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Vancomycin.Approved, Vet Approved
AllobarbitalThe risk or severity of adverse effects can be increased when Allobarbital is combined with Vancomycin.Experimental
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with Vancomycin.Investigational
AlminoprofenAlminoprofen may decrease the excretion rate of Vancomycin which could result in a higher serum level.Experimental
AlmotriptanThe risk or severity of adverse effects can be increased when Vancomycin is combined with Almotriptan.Approved, Investigational
AlosetronThe risk or severity of adverse effects can be increased when Vancomycin is combined with Alosetron.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Vancomycin.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Vancomycin.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Vancomycin.Approved, Illicit, Investigational
AlprenololThe risk or severity of adverse effects can be increased when Vancomycin is combined with Alprenolol.Approved, Withdrawn
AlverineThe risk or severity of adverse effects can be increased when Vancomycin is combined with Alverine.Approved, Investigational
AmikacinThe risk or severity of adverse effects can be increased when Amikacin is combined with Vancomycin.Approved, Investigational, Vet Approved
AmineptineThe risk or severity of adverse effects can be increased when Amineptine is combined with Vancomycin.Illicit, Withdrawn
AminophenazoneAminophenazone may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Withdrawn
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Vancomycin.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Vancomycin.Approved
AmitriptylinoxideThe risk or severity of adverse effects can be increased when Amitriptylinoxide is combined with Vancomycin.Approved, Investigational
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Vancomycin.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Vancomycin.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Vancomycin.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Vancomycin.Approved, Illicit, Investigational
Amphotericin BThe risk or severity of nephrotoxicity can be increased when Amphotericin B is combined with Vancomycin.Approved, Investigational
AniracetamThe risk or severity of adverse effects can be increased when Aniracetam is combined with Vancomycin.Experimental
AntipyrineAntipyrine may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Investigational
AntrafenineAntrafenine may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
APD791The risk or severity of adverse effects can be increased when Vancomycin is combined with APD791.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Vancomycin is combined with Apomorphine.Approved, Investigational
ApramycinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Apramycin.Experimental, Vet Approved
AprobarbitalThe risk or severity of adverse effects can be increased when Aprobarbital is combined with Vancomycin.Approved, Illicit
ApronalideThe risk or severity of adverse effects can be increased when Apronalide is combined with Vancomycin.Experimental
Arbaclofen PlacarbilThe risk or severity of adverse effects can be increased when Arbaclofen Placarbil is combined with Vancomycin.Investigational
ArbekacinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Arbekacin.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Vancomycin.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of adverse effects can be increased when Aripiprazole lauroxil is combined with Vancomycin.Approved, Investigational
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Vancomycin.Approved
AtomoxetineThe risk or severity of adverse effects can be increased when Atomoxetine is combined with Vancomycin.Approved
AtracuriumThe therapeutic efficacy of Atracurium can be increased when used in combination with Vancomycin.Approved, Experimental, Investigational
Atracurium besylateThe therapeutic efficacy of Atracurium besylate can be increased when used in combination with Vancomycin.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Vancomycin.Investigational, Vet Approved
AzapropazoneAzapropazone may decrease the excretion rate of Vancomycin which could result in a higher serum level.Withdrawn
AZD-3043The risk or severity of adverse effects can be increased when AZD-3043 is combined with Vancomycin.Investigational
AzelastineVancomycin may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Bacillus calmette-guerin substrain connaught live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Vancomycin.Approved, Investigational
Bacillus calmette-guerin substrain danish 1331 live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain danish 1331 live antigen can be decreased when used in combination with Vancomycin.Investigational
Bacillus calmette-guerin substrain tice live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Vancomycin.Approved
BacitracinThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Bacitracin.Approved, Vet Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Vancomycin.Approved
BalsalazideBalsalazide may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Investigational
BarbexacloneThe risk or severity of adverse effects can be increased when Barbexaclone is combined with Vancomycin.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Vancomycin.Illicit
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Vancomycin.Investigational
BeclamideThe risk or severity of adverse effects can be increased when Beclamide is combined with Vancomycin.Experimental
BekanamycinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Bekanamycin.Experimental
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Vancomycin.Withdrawn
BendazacBendazac may decrease the excretion rate of Vancomycin which could result in a higher serum level.Experimental
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Vancomycin.Withdrawn
BenorilateBenorilate may decrease the excretion rate of Vancomycin which could result in a higher serum level.Experimental
BenoxaprofenBenoxaprofen may decrease the excretion rate of Vancomycin which could result in a higher serum level.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with Vancomycin.Approved, Investigational
BenzoctamineThe risk or severity of adverse effects can be increased when Benzoctamine is combined with Vancomycin.Approved
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Vancomycin.Approved, Illicit
BenzydamineBenzydamine may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Vancomycin.Approved
BifemelaneThe risk or severity of adverse effects can be increased when Bifemelane is combined with Vancomycin.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when Bifeprunox is combined with Vancomycin.Investigational
BL-1020The risk or severity of adverse effects can be increased when BL-1020 is combined with Vancomycin.Investigational
BlonanserinThe risk or severity of adverse effects can be increased when Blonanserin is combined with Vancomycin.Approved, Investigational
Botulinum Toxin Type AThe risk or severity of adverse effects can be increased when Vancomycin is combined with Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when Vancomycin is combined with Botulinum Toxin Type B.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Brexpiprazole is combined with Vancomycin.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Vancomycin.Approved
BrivaracetamThe risk or severity of adverse effects can be increased when Brivaracetam is combined with Vancomycin.Approved, Investigational
BrofaromineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Vancomycin.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Vancomycin.Approved, Illicit, Investigational
BromfenacBromfenac may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with Vancomycin.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Vancomycin is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with Vancomycin.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Vancomycin.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Vancomycin.Approved, Investigational, Withdrawn
BufexamacBufexamac may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Experimental
BufotenineThe risk or severity of adverse effects can be increased when Bufotenine is combined with Vancomycin.Experimental, Illicit
BumadizoneBumadizone may decrease the excretion rate of Vancomycin which could result in a higher serum level.Experimental
BuprenorphineVancomycin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Vancomycin.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Vancomycin.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Vancomycin.Approved, Illicit
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Vancomycin.Approved, Illicit
ButaperazineThe risk or severity of adverse effects can be increased when Butaperazine is combined with Vancomycin.Experimental
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Vancomycin.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Vancomycin.Approved, Illicit, Vet Approved
ButriptylineThe risk or severity of adverse effects can be increased when Butriptyline is combined with Vancomycin.Approved
CabergolineThe risk or severity of adverse effects can be increased when Vancomycin is combined with Cabergoline.Approved
CamazepamThe risk or severity of adverse effects can be increased when Camazepam is combined with Vancomycin.Approved, Illicit
CannabidiolThe risk or severity of adverse effects can be increased when Vancomycin is combined with Cannabidiol.Approved, Investigational
CannabidivarinThe risk or severity of adverse effects can be increased when Cannabidivarin is combined with Vancomycin.Investigational
CapreomycinThe risk or severity of adverse effects can be increased when Capreomycin is combined with Vancomycin.Approved
CaptodiameThe risk or severity of adverse effects can be increased when Captodiame is combined with Vancomycin.Approved, Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Vancomycin.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may decrease the excretion rate of Vancomycin which could result in a higher serum level.Experimental, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Vancomycin.Approved
CarboplatinThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Carboplatin.Approved
CarbromalThe risk or severity of adverse effects can be increased when Carbromal is combined with Vancomycin.Experimental
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Vancomycin.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Cariprazine is combined with Vancomycin.Approved, Investigational
CarisbamateThe risk or severity of adverse effects can be increased when Carisbamate is combined with Vancomycin.Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Vancomycin.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Vancomycin.Withdrawn
CarprofenCarprofen may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Vet Approved, Withdrawn
CathinoneThe risk or severity of adverse effects can be increased when Cathinone is combined with Vancomycin.Illicit
CefacetrileThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Cefacetrile.Approved
CefaclorThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Cefaclor.Approved
CefadroxilThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Cefadroxil.Approved, Vet Approved, Withdrawn
CefalotinThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Cefalotin.Approved, Investigational, Vet Approved
CefamandoleThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Cefamandole.Approved, Investigational
CefapirinThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Cefapirin.Approved, Vet Approved
CefatrizineThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Cefatrizine.Experimental
CefazedoneThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Cefazedone.Experimental
CefazolinThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Cefazolin.Approved
CefbuperazoneThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Cefbuperazone.Experimental
CefcapeneThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Cefcapene.Experimental
CefditorenThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Cefditoren.Approved, Investigational
CefepimeThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Cefepime.Approved, Investigational
CefetametThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Cefetamet.Experimental
CefmenoximeThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Cefmenoxime.Approved
CefmetazoleThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Cefmetazole.Approved, Investigational
CefminoxThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Cefminox.Approved
CefodizimeThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Cefodizime.Experimental
CefonicidThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Cefonicid.Approved, Investigational
CefoperazoneThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Cefoperazone.Approved, Investigational
CeforanideThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Ceforanide.Approved
CefotaximeThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Cefotaxime.Approved
CefotetanThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Cefotetan.Approved
CefotiamThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Cefotiam.Approved, Investigational
CefoxitinThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Cefoxitin.Approved
CefozopranThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Cefozopran.Experimental
CefpiramideThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Cefpiramide.Approved
CefpiromeThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Cefpirome.Approved
CefpodoximeThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Cefpodoxime.Approved, Vet Approved
CefprozilThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Cefprozil.Approved
CefradineThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Cefradine.Approved
CefroxadineThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Cefroxadine.Withdrawn
CefsulodinThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Cefsulodin.Experimental
Ceftaroline fosamilThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Ceftaroline fosamil.Approved, Investigational
CeftazidimeThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Ceftazidime.Approved
CeftezoleThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Ceftezole.Experimental
CeftibutenThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Ceftibuten.Approved, Investigational
CeftizoximeThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Ceftizoxime.Approved, Investigational
CeftobiproleThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Ceftobiprole.Approved, Investigational
CeftriaxoneThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Ceftriaxone.Approved
CefuroximeThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Cefuroxime.Approved
CelecoxibCelecoxib may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Investigational
CephalexinThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Cephalexin.Approved, Investigational, Vet Approved
CephaloglycinThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Cephaloglycin.Approved
CephaloridineThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Cephaloridine.Approved, Withdrawn
Cephalothin GroupThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Cephalothin Group.Experimental
CerlapirdineThe risk or severity of adverse effects can be increased when Vancomycin is combined with Cerlapirdine.Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Vancomycin.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Vancomycin.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Vancomycin.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Vancomycin.Approved, Investigational, Withdrawn
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Vancomycin.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Vancomycin.Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Chlorphenesin is combined with Vancomycin.Approved, Vet Approved, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Chlorproethazine is combined with Vancomycin.Experimental
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Vancomycin.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Vancomycin.Approved, Investigational, Withdrawn
ChlortetracyclineThe risk or severity of adverse effects can be increased when Chlortetracycline is combined with Vancomycin.Approved, Investigational, Vet Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Vancomycin.Approved
CholestyramineThe therapeutic efficacy of Vancomycin can be decreased when used in combination with Cholestyramine.Approved, Investigational
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
CilansetronThe risk or severity of adverse effects can be increased when Vancomycin is combined with Cilansetron.Investigational
CimicoxibCimicoxib may decrease the excretion rate of Vancomycin which could result in a higher serum level.Investigational
CinitaprideThe risk or severity of adverse effects can be increased when Vancomycin is combined with Cinitapride.Approved, Investigational
CinolazepamThe risk or severity of adverse effects can be increased when Cinolazepam is combined with Vancomycin.Approved
CisaprideThe risk or severity of adverse effects can be increased when Vancomycin is combined with Cisapride.Approved, Investigational, Withdrawn
CisatracuriumThe therapeutic efficacy of Cisatracurium can be increased when used in combination with Vancomycin.Approved
CisplatinThe risk or severity of nephrotoxicity can be increased when Cisplatin is combined with Vancomycin.Approved
CitalopramThe risk or severity of adverse effects can be increased when Vancomycin is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Vancomycin.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Vancomycin.Approved
ClindamycinThe risk or severity of adverse effects can be increased when Clindamycin is combined with Vancomycin.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Vancomycin.Approved, Illicit
Clodronic AcidThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Vancomycin is combined with Clodronic Acid.Approved, Investigational, Vet Approved
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Vancomycin.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Vancomycin.Approved, Investigational, Vet Approved
ClomocyclineThe risk or severity of adverse effects can be increased when Clomocycline is combined with Vancomycin.Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Vancomycin.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Vancomycin.Approved
ClonixinClonixin may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with Vancomycin.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Vancomycin.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with Vancomycin.Experimental
ClotiazepamThe risk or severity of adverse effects can be increased when Clotiazepam is combined with Vancomycin.Approved, Illicit
CloxazolamThe risk or severity of adverse effects can be increased when Cloxazolam is combined with Vancomycin.Approved, Investigational
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Vancomycin.Approved
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Vancomycin.Approved, Illicit
ColesevelamThe therapeutic efficacy of Vancomycin can be decreased when used in combination with Colesevelam.Approved
ColestipolThe therapeutic efficacy of Vancomycin can be decreased when used in combination with Colestipol.Approved
ColistimethateVancomycin may increase the nephrotoxic activities of Colistimethate.Approved, Vet Approved
ColistinThe risk or severity of adverse effects can be increased when Colistin is combined with Vancomycin.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Cyamemazine is combined with Vancomycin.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Vancomycin.Approved
CyclobarbitalThe risk or severity of adverse effects can be increased when Cyclobarbital is combined with Vancomycin.Experimental
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Vancomycin.Approved
CyclopentamineThe risk or severity of adverse effects can be increased when Vancomycin is combined with Cyclopentamine.Withdrawn
CyclopropaneThe risk or severity of adverse effects can be increased when Cyclopropane is combined with Vancomycin.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when Vancomycin is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Vancomycin.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Vancomycin.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Vancomycin.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Vancomycin is combined with Dapoxetine.Investigational
DeanolThe risk or severity of adverse effects can be increased when Deanol is combined with Vancomycin.Experimental
DecamethoniumThe therapeutic efficacy of Decamethonium can be increased when used in combination with Vancomycin.Approved
DelorazepamThe risk or severity of adverse effects can be increased when Delorazepam is combined with Vancomycin.Approved, Illicit, Investigational
DemeclocyclineThe risk or severity of adverse effects can be increased when Demeclocycline is combined with Vancomycin.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with Vancomycin.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Vancomycin.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Vancomycin.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Vancomycin.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Vancomycin is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Vancomycin.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Vancomycin.Approved
DexibuprofenDexibuprofen may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Investigational
DexketoprofenDexketoprofen may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Investigational
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Vancomycin.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Vancomycin is combined with Dexmethylphenidate.Approved, Investigational
DextofisopamThe risk or severity of adverse effects can be increased when Dextofisopam is combined with Vancomycin.Investigational
DextromethorphanThe risk or severity of adverse effects can be increased when Vancomycin is combined with Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Vancomycin.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Vancomycin.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Vancomycin.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Vancomycin.Approved, Illicit, Investigational, Vet Approved
DibekacinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Dibekacin.Experimental
DibenzepinThe risk or severity of adverse effects can be increased when Dibenzepin is combined with Vancomycin.Experimental
DichloralphenazoneThe risk or severity of adverse effects can be increased when Dichloralphenazone is combined with Vancomycin.Approved, Illicit
DiclofenacDiclofenac may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with Vancomycin.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Vancomycin.Approved, Illicit
DifenpiramideDifenpiramide may decrease the excretion rate of Vancomycin which could result in a higher serum level.Experimental
DiflunisalDiflunisal may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Vancomycin.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Vancomycin is combined with Dihydroergotamine.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Vancomycin.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Vancomycin.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Dihydrostreptomycin.Investigational, Vet Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Vancomycin.Approved
DimetacrineThe risk or severity of adverse effects can be increased when Dimetacrine is combined with Vancomycin.Approved, Withdrawn
DimethyltryptamineThe risk or severity of adverse effects can be increased when Dimethyltryptamine is combined with Vancomycin.Experimental, Illicit
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Vancomycin.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Vancomycin.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with Vancomycin.Experimental
DolasetronThe risk or severity of adverse effects can be increased when Vancomycin is combined with Dolasetron.Approved, Investigational
Domoic AcidThe risk or severity of adverse effects can be increased when Domoic Acid is combined with Vancomycin.Experimental
DonepezilThe risk or severity of adverse effects can be increased when Donepezil is combined with Vancomycin.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Vancomycin.Vet Approved
DosulepinThe risk or severity of adverse effects can be increased when Dosulepin is combined with Vancomycin.Approved
DotarizineThe risk or severity of adverse effects can be increased when Vancomycin is combined with Dotarizine.Investigational
DoxacuriumThe therapeutic efficacy of Doxacurium can be increased when used in combination with Vancomycin.Approved
DoxefazepamThe risk or severity of adverse effects can be increased when Doxefazepam is combined with Vancomycin.Experimental
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Vancomycin.Approved, Investigational
DoxycyclineThe risk or severity of adverse effects can be increased when Doxycycline is combined with Vancomycin.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Vancomycin.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Vancomycin.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Vancomycin.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Vancomycin.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Vancomycin.Experimental, Illicit
DroxicamDroxicam may decrease the excretion rate of Vancomycin which could result in a higher serum level.Withdrawn
DuloxetineThe risk or severity of adverse effects can be increased when Vancomycin is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Vancomycin.Approved
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with Vancomycin.Investigational
EdivoxetineThe risk or severity of adverse effects can be increased when Edivoxetine is combined with Vancomycin.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Vancomycin.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Vancomycin is combined with Eletriptan.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with Vancomycin.Investigational
EltoprazineThe risk or severity of adverse effects can be increased when Vancomycin is combined with Eltoprazine.Investigational
EmeproniumThe risk or severity of adverse effects can be increased when Emepronium is combined with Vancomycin.Experimental
EmylcamateThe risk or severity of adverse effects can be increased when Emylcamate is combined with Vancomycin.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Vancomycin.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Vancomycin.Approved, Investigational
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with Vancomycin.Approved, Investigational
EpinastineThe risk or severity of adverse effects can be increased when Vancomycin is combined with Epinastine.Approved, Investigational
EpirizoleEpirizole may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
EplivanserinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Eplivanserin.Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Vancomycin is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Vancomycin is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Vancomycin is combined with Ergotamine.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Vancomycin is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe risk or severity of adverse effects can be increased when Eslicarbazepine acetate is combined with Vancomycin.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when Esmirtazapine is combined with Vancomycin.Investigational
EsreboxetineThe risk or severity of adverse effects can be increased when Esreboxetine is combined with Vancomycin.Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Vancomycin.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Vancomycin.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Vancomycin.Approved, Investigational
EthadioneThe risk or severity of adverse effects can be increased when Ethadione is combined with Vancomycin.Experimental
EthanolVancomycin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Vancomycin.Approved, Illicit, Withdrawn
EthenzamideEthenzamide may decrease the excretion rate of Vancomycin which could result in a higher serum level.Experimental
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Vancomycin.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Vancomycin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Vancomycin.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with Vancomycin.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Vancomycin.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Vancomycin.Approved, Illicit
Etidronic acidThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Vancomycin is combined with Etidronic acid.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Vancomycin.Investigational, Withdrawn
EtiracetamThe risk or severity of adverse effects can be increased when Etiracetam is combined with Vancomycin.Investigational
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Vancomycin.Approved
EtodolacEtodolac may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Investigational
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Vancomycin.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Etoperidone is combined with Vancomycin.Withdrawn
EtoricoxibEtoricoxib may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Vancomycin.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Vancomycin.Approved, Investigational
FabomotizoleThe risk or severity of adverse effects can be increased when Fabomotizole is combined with Vancomycin.Experimental
Fazadinium bromideThe risk or severity of adverse effects can be increased when Fazadinium bromide is combined with Vancomycin.Experimental
FebarbamateThe risk or severity of adverse effects can be increased when Febarbamate is combined with Vancomycin.Experimental
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Vancomycin.Approved
FelbinacFelbinac may decrease the excretion rate of Vancomycin which could result in a higher serum level.Experimental
FenbufenFenbufen may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Vancomycin.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Vancomycin is combined with Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FenoprofenFenoprofen may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Vancomycin.Approved, Illicit, Investigational, Vet Approved
FentiazacFentiazac may decrease the excretion rate of Vancomycin which could result in a higher serum level.Experimental
FenyramidolThe risk or severity of adverse effects can be increased when Fenyramidol is combined with Vancomycin.Experimental
FeprazoneFeprazone may decrease the excretion rate of Vancomycin which could result in a higher serum level.Experimental
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Vancomycin.Approved, Investigational
FirocoxibFirocoxib may decrease the excretion rate of Vancomycin which could result in a higher serum level.Experimental, Vet Approved
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Vancomycin.Approved, Investigational
FloctafenineFloctafenine may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Withdrawn
FlomoxefThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Flomoxef.Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with Vancomycin.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Vancomycin.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Vancomycin.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Vancomycin.Approved, Illicit
FlunixinFlunixin may decrease the excretion rate of Vancomycin which could result in a higher serum level.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the excretion rate of Vancomycin which could result in a higher serum level.Experimental
FluoxetineThe risk or severity of adverse effects can be increased when Vancomycin is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Vancomycin.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Vancomycin.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Vancomycin.Approved, Illicit, Investigational
FlurbiprofenFlurbiprofen may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Vancomycin.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Vancomycin.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Vancomycin is combined with Fluvoxamine.Approved, Investigational
FoscarnetThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Foscarnet.Approved
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Vancomycin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Vancomycin.Approved, Illicit, Investigational
FramycetinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Framycetin.Approved
FrovatriptanThe risk or severity of adverse effects can be increased when Vancomycin is combined with Frovatriptan.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Vancomycin.Approved, Investigational, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Vancomycin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Vancomycin.Approved, Investigational
GaboxadolThe risk or severity of adverse effects can be increased when Gaboxadol is combined with Vancomycin.Investigational
GallamineThe therapeutic efficacy of Gallamine can be increased when used in combination with Vancomycin.Experimental
Gallamine TriethiodideThe therapeutic efficacy of Gallamine Triethiodide can be increased when used in combination with Vancomycin.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Vancomycin.Approved, Illicit, Investigational
Gantacurium ChlorideThe risk or severity of adverse effects can be increased when Gantacurium Chloride is combined with Vancomycin.Investigational
GedocarnilThe risk or severity of adverse effects can be increased when Gedocarnil is combined with Vancomycin.Experimental
GeneticinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Geneticin.Experimental
GentamicinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when Vancomycin is combined with GENTAMICIN C1A.Experimental
GepironeThe risk or severity of adverse effects can be increased when Gepirone is combined with Vancomycin.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Vancomycin.Approved, Illicit
GranisetronThe risk or severity of adverse effects can be increased when Vancomycin is combined with Granisetron.Approved, Investigational
GuacetisalGuacetisal may decrease the excretion rate of Vancomycin which could result in a higher serum level.Experimental
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Vancomycin.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Vancomycin.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Vancomycin.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Vancomycin.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Harmaline is combined with Vancomycin.Experimental
HeptabarbitalThe risk or severity of adverse effects can be increased when Heptabarbital is combined with Vancomycin.Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Vancomycin.Approved, Illicit, Investigational
HexafluroniumThe risk or severity of adverse effects can be increased when Hexafluronium is combined with Vancomycin.Approved
HexamethoniumThe risk or severity of adverse effects can be increased when Vancomycin is combined with Hexamethonium.Experimental
HexapropymateThe risk or severity of adverse effects can be increased when Hexapropymate is combined with Vancomycin.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Vancomycin.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Vancomycin.Experimental
HydrocodoneVancomycin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
Hydrolyzed CephalothinThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Hydrolyzed Cephalothin.Experimental
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Vancomycin.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Vancomycin.Approved
Hygromycin BThe risk or severity of adverse effects can be increased when Vancomycin is combined with Hygromycin B.Vet Approved
HypericinThe risk or severity of adverse effects can be increased when Hypericin is combined with Vancomycin.Investigational
IbandronateThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Vancomycin is combined with Ibandronate.Approved, Investigational
IbuprofenIbuprofen may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
IbuproxamIbuproxam may decrease the excretion rate of Vancomycin which could result in a higher serum level.Withdrawn
IcosapentIcosapent may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Nutraceutical
IdalopirdineThe risk or severity of adverse effects can be increased when Vancomycin is combined with Idalopirdine.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when Ifenprodil is combined with Vancomycin.Approved, Investigational, Withdrawn
IferanserinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Iferanserin.Investigational
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Vancomycin.Approved
ImagabalinThe risk or severity of adverse effects can be increased when Imagabalin is combined with Vancomycin.Investigational
Imidazole salicylateImidazole salicylate may decrease the excretion rate of Vancomycin which could result in a higher serum level.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Vancomycin.Approved
Imipramine oxideThe risk or severity of adverse effects can be increased when Imipramine oxide is combined with Vancomycin.Experimental
Incadronic acidThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Vancomycin is combined with Incadronic acid.Approved, Investigational
IndalpineThe risk or severity of adverse effects can be increased when Vancomycin is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with Vancomycin.Investigational
IndobufenIndobufen may decrease the excretion rate of Vancomycin which could result in a higher serum level.Investigational
IndomethacinIndomethacin may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Investigational
IndoprofenIndoprofen may decrease the excretion rate of Vancomycin which could result in a higher serum level.Withdrawn
IprazochromeThe risk or severity of adverse effects can be increased when Vancomycin is combined with Iprazochrome.Experimental
IprindoleThe risk or severity of adverse effects can be increased when Iprindole is combined with Vancomycin.Experimental
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Vancomycin.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Vancomycin.Withdrawn
IsepamicinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Isepamicin.Experimental
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Vancomycin.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Vancomycin.Approved, Vet Approved
IsoxicamIsoxicam may decrease the excretion rate of Vancomycin which could result in a higher serum level.Withdrawn
KanamycinThe risk or severity of adverse effects can be increased when Kanamycin is combined with Vancomycin.Approved, Investigational, Vet Approved
KebuzoneKebuzone may decrease the excretion rate of Vancomycin which could result in a higher serum level.Experimental
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Vancomycin.Approved, Vet Approved
KetanserinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Ketanserin.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Vancomycin.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Vancomycin.Approved, Investigational
KetoprofenKetoprofen may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Vet Approved
KetorolacKetorolac may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Vancomycin.Approved, Nutraceutical, Withdrawn
LacosamideThe risk or severity of adverse effects can be increased when Lacosamide is combined with Vancomycin.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Vancomycin.Approved, Investigational
LanicemineThe risk or severity of adverse effects can be increased when Lanicemine is combined with Vancomycin.Investigational
LasmiditanThe risk or severity of adverse effects can be increased when Vancomycin is combined with Lasmiditan.Investigational
LatamoxefThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Latamoxef.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Vancomycin.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Vancomycin is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with Vancomycin.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Vancomycin.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Vancomycin.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Vancomycin is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Vancomycin.Approved
LincomycinThe risk or severity of adverse effects can be increased when Lincomycin is combined with Vancomycin.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Vancomycin is combined with Linezolid.Approved, Investigational
LisurideThe risk or severity of adverse effects can be increased when Vancomycin is combined with Lisuride.Approved, Investigational
Lithium carbonateThe risk or severity of adverse effects can be increased when Vancomycin is combined with Lithium carbonate.Approved
Lithium cationThe risk or severity of adverse effects can be increased when Lithium cation is combined with Vancomycin.Experimental
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Vancomycin.Illicit
LofepramineThe risk or severity of adverse effects can be increased when Lofepramine is combined with Vancomycin.Experimental
LofexidineThe therapeutic efficacy of Vancomycin can be increased when used in combination with Lofexidine.Approved, Investigational
LonazolacLonazolac may decrease the excretion rate of Vancomycin which could result in a higher serum level.Experimental
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with Vancomycin.Experimental
LoracarbefThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Loracarbef.Investigational, Withdrawn
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Vancomycin.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Vancomycin.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with Vancomycin.Approved
LornoxicamLornoxicam may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Investigational
LortalamineThe risk or severity of adverse effects can be increased when Lortalamine is combined with Vancomycin.Experimental
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Vancomycin.Approved
LoxoprofenLoxoprofen may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Investigational
LumateperoneThe risk or severity of adverse effects can be increased when Lumateperone is combined with Vancomycin.Investigational
LumiracoxibLumiracoxib may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Vancomycin.Approved, Investigational
LymecyclineThe risk or severity of adverse effects can be increased when Lymecycline is combined with Vancomycin.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Vancomycin.Illicit, Investigational, Withdrawn
m-ChlorophenylpiperazineThe risk or severity of adverse effects can be increased when Vancomycin is combined with m-Chlorophenylpiperazine.Investigational
Magnesium acetateThe risk or severity of adverse effects can be increased when Vancomycin is combined with Magnesium acetate.Approved
Magnesium acetate tetrahydrateThe risk or severity of adverse effects can be increased when Vancomycin is combined with Magnesium acetate tetrahydrate.Approved
Magnesium Aluminum SilicateThe risk or severity of adverse effects can be increased when Vancomycin is combined with Magnesium Aluminum Silicate.Approved
Magnesium aspartateThe risk or severity of adverse effects can be increased when Vancomycin is combined with Magnesium aspartate.Experimental
Magnesium carbonateThe risk or severity of adverse effects can be increased when Vancomycin is combined with Magnesium carbonate.Approved, Investigational
Magnesium cationThe risk or severity of adverse effects can be increased when Vancomycin is combined with Magnesium cation.Approved, Nutraceutical
Magnesium chlorideThe risk or severity of adverse effects can be increased when Vancomycin is combined with Magnesium chloride.Approved
Magnesium citrateThe risk or severity of adverse effects can be increased when Vancomycin is combined with Magnesium citrate.Approved
Magnesium gluconateThe risk or severity of adverse effects can be increased when Vancomycin is combined with Magnesium gluconate.Approved, Investigational
Magnesium glycinateThe risk or severity of adverse effects can be increased when Vancomycin is combined with Magnesium glycinate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when Vancomycin is combined with Magnesium hydroxide.Approved, Investigational
Magnesium orotateThe risk or severity of adverse effects can be increased when Vancomycin is combined with Magnesium orotate.Experimental
Magnesium oxideThe risk or severity of adverse effects can be increased when Vancomycin is combined with Magnesium oxide.Approved
Magnesium phosphateThe risk or severity of adverse effects can be increased when Vancomycin is combined with Magnesium phosphate.Experimental
Magnesium salicylateMagnesium salicylate may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
Magnesium silicateThe risk or severity of adverse effects can be increased when Vancomycin is combined with Magnesium silicate.Approved
Magnesium stearateThe risk or severity of adverse effects can be increased when Vancomycin is combined with Magnesium stearate.Investigational
Magnesium sulfateThe therapeutic efficacy of Vancomycin can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Vancomycin is combined with Magnesium Trisilicate.Approved
MannitolThe risk or severity of nephrotoxicity can be increased when Mannitol is combined with Vancomycin.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Vancomycin.Approved, Investigational
MazindolThe risk or severity of adverse effects can be increased when Mazindol is combined with Vancomycin.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Vancomycin.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with Vancomycin.Experimental
MebutamateThe risk or severity of adverse effects can be increased when Mebutamate is combined with Vancomycin.Approved
MecamylamineThe risk or severity of adverse effects can be increased when Vancomycin is combined with Mecamylamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Vancomycin.Approved
Meclofenamic acidMeclofenamic acid may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Vet Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with Vancomycin.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Vancomycin.Vet Approved
MedifoxamineThe risk or severity of adverse effects can be increased when Medifoxamine is combined with Vancomycin.Experimental
Mefenamic acidMefenamic acid may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Vancomycin.Approved, Nutraceutical, Vet Approved
MelitracenThe risk or severity of adverse effects can be increased when Melitracen is combined with Vancomycin.Experimental, Investigational
MeloxicamMeloxicam may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Vancomycin.Approved, Investigational
MephenesinThe risk or severity of adverse effects can be increased when Mephenesin is combined with Vancomycin.Approved
MephenoxaloneThe risk or severity of adverse effects can be increased when Mephenoxalone is combined with Vancomycin.Experimental
MephenytoinThe risk or severity of adverse effects can be increased when Mephenytoin is combined with Vancomycin.Investigational, Withdrawn
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Vancomycin.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Vancomycin.Experimental
MesalazineMesalazine may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Vancomycin.Approved, Investigational
MetamizoleMetamizole may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Investigational, Withdrawn
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Vancomycin.Approved
MetergolineThe risk or severity of adverse effects can be increased when Vancomycin is combined with Metergoline.Experimental
MethacyclineThe risk or severity of adverse effects can be increased when Methacycline is combined with Vancomycin.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Vancomycin.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Vancomycin.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Methamphetamine is combined with Vancomycin.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Vancomycin.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Vancomycin.Illicit, Withdrawn
MetharbitalThe risk or severity of adverse effects can be increased when Metharbital is combined with Vancomycin.Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Vancomycin.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Vancomycin.Approved
MethotrimeprazineVancomycin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Vancomycin.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Vancomycin.Approved
Methylene blueThe risk or severity of adverse effects can be increased when Methylene blue is combined with Vancomycin.Approved, Investigational
MethylpentynolThe risk or severity of adverse effects can be increased when Methylpentynol is combined with Vancomycin.Experimental
MethylphenidateThe risk or severity of adverse effects can be increased when Vancomycin is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Vancomycin.Approved
MethyprylonThe risk or severity of adverse effects can be increased when Methyprylon is combined with Vancomycin.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when Vancomycin is combined with Methysergide.Approved
MetocurineThe therapeutic efficacy of Metocurine can be increased when used in combination with Vancomycin.Approved
Metocurine IodideThe therapeutic efficacy of Metocurine Iodide can be increased when used in combination with Vancomycin.Approved, Withdrawn
MetyrosineVancomycin may increase the sedative activities of Metyrosine.Approved
MianserinThe risk or severity of adverse effects can be increased when Mianserin is combined with Vancomycin.Approved, Investigational
MicronomicinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Micronomicin.Experimental
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Vancomycin.Approved, Illicit
MidomafetamineThe risk or severity of adverse effects can be increased when Midomafetamine is combined with Vancomycin.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Vancomycin is combined with Milnacipran.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Vancomycin.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Vancomycin.Approved, Investigational
MirtazapineVancomycin may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MivacuriumThe therapeutic efficacy of Mivacurium can be increased when used in combination with Vancomycin.Approved
MK-212The risk or severity of adverse effects can be increased when Vancomycin is combined with MK-212.Investigational
MMDAThe risk or severity of adverse effects can be increased when Vancomycin is combined with MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Vancomycin.Approved, Investigational
MofebutazoneMofebutazone may decrease the excretion rate of Vancomycin which could result in a higher serum level.Experimental
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Vancomycin.Approved
MoperoneThe risk or severity of adverse effects can be increased when Moperone is combined with Vancomycin.Experimental
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Vancomycin.Approved, Investigational, Withdrawn
MorniflumateMorniflumate may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Vancomycin.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Mosapramine is combined with Vancomycin.Experimental
MosaprideThe risk or severity of adverse effects can be increased when Vancomycin is combined with Mosapride.Investigational
MRK-409The risk or severity of adverse effects can be increased when MRK-409 is combined with Vancomycin.Experimental
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamineThe risk or severity of adverse effects can be increased when Vancomycin is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Vancomycin.Approved, Investigational
NabumetoneNabumetone may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
NaftidrofurylThe risk or severity of adverse effects can be increased when Vancomycin is combined with Naftidrofuryl.Experimental
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Vancomycin.Approved
NaluzotanThe risk or severity of adverse effects can be increased when Vancomycin is combined with Naluzotan.Investigational
NaproxenNaproxen may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Vet Approved
NaratriptanThe risk or severity of adverse effects can be increased when Vancomycin is combined with Naratriptan.Approved, Investigational
NaronaprideThe risk or severity of adverse effects can be increased when Vancomycin is combined with Naronapride.Investigational
NeamineThe risk or severity of adverse effects can be increased when Vancomycin is combined with Neamine.Experimental
NefazodoneThe risk or severity of adverse effects can be increased when Vancomycin is combined with Nefazodone.Approved, Withdrawn
NefiracetamThe risk or severity of adverse effects can be increased when Nefiracetam is combined with Vancomycin.Investigational
NeocitrullamonThe risk or severity of adverse effects can be increased when Neocitrullamon is combined with Vancomycin.Experimental
NeomycinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinThe therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Vancomycin.Investigational
NepafenacNepafenac may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Investigational
NetilmicinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Netilmicin.Approved, Investigational
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Vancomycin.Withdrawn
NiaprazineThe risk or severity of adverse effects can be increased when Niaprazine is combined with Vancomycin.Experimental
NicotineThe risk or severity of adverse effects can be increased when Vancomycin is combined with Nicotine.Approved
NifenazoneNifenazone may decrease the excretion rate of Vancomycin which could result in a higher serum level.Experimental
Niflumic AcidNiflumic Acid may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
NimesulideNimesulide may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Investigational, Withdrawn
NisoxetineThe risk or severity of adverse effects can be increased when Nisoxetine is combined with Vancomycin.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Vancomycin.Approved
NitroaspirinNitroaspirin may decrease the excretion rate of Vancomycin which could result in a higher serum level.Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Vancomycin.Approved, Vet Approved
NomifensineThe risk or severity of adverse effects can be increased when Nomifensine is combined with Vancomycin.Withdrawn
NordazepamThe risk or severity of adverse effects can be increased when Nordazepam is combined with Vancomycin.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Vancomycin.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Vancomycin.Approved
NS-398NS-398 may decrease the excretion rate of Vancomycin which could result in a higher serum level.Experimental
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Vancomycin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Vancomycin.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Vancomycin.Approved
OlsalazineOlsalazine may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Vancomycin.Approved
OpipramolThe risk or severity of adverse effects can be increased when Opipramol is combined with Vancomycin.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Vancomycin.Approved, Illicit
OrphenadrineVancomycin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OrvepitantThe risk or severity of adverse effects can be increased when Orvepitant is combined with Vancomycin.Investigational
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Vancomycin.Investigational
OxaflozaneThe risk or severity of adverse effects can be increased when Oxaflozane is combined with Vancomycin.Experimental
OxaprotilineThe risk or severity of adverse effects can be increased when Oxaprotiline is combined with Vancomycin.Experimental
OxaprozinOxaprozin may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Vancomycin.Approved
OxcarbazepineThe risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Vancomycin.Approved
OxiracetamThe risk or severity of adverse effects can be increased when Oxiracetam is combined with Vancomycin.Experimental
OxitriptanThe risk or severity of adverse effects can be increased when Oxitriptan is combined with Vancomycin.Approved, Investigational, Nutraceutical
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Vancomycin.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Vancomycin.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Vancomycin.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Oxypertine is combined with Vancomycin.Experimental
OxyphenbutazoneOxyphenbutazone may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Withdrawn
OxytetracyclineThe risk or severity of adverse effects can be increased when Oxytetracycline is combined with Vancomycin.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Vancomycin.Approved
PalonosetronThe risk or severity of adverse effects can be increased when Vancomycin is combined with Palonosetron.Approved, Investigational
PamidronateThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Vancomycin is combined with Pamidronate.Approved
PancuroniumThe therapeutic efficacy of Pancuronium can be increased when used in combination with Vancomycin.Approved
ParaldehydeVancomycin may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethadioneThe risk or severity of adverse effects can be increased when Paramethadione is combined with Vancomycin.Approved
ParecoxibParecoxib may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Vancomycin.Approved
ParomomycinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Vancomycin is combined with Paroxetine.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Vancomycin is combined with Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with Vancomycin.Experimental
PenimepicyclineThe risk or severity of adverse effects can be increased when Penimepicycline is combined with Vancomycin.Experimental
PentamidineThe risk or severity of nephrotoxicity can be increased when Vancomycin is combined with Pentamidine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Vancomycin.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Vancomycin.Approved, Investigational, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Vancomycin is combined with Pentolinium.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Vancomycin.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Vancomycin.Approved, Investigational
PergolideThe risk or severity of adverse effects can be increased when Vancomycin is combined with Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Vancomycin.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Vancomycin.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Vancomycin.Approved
PhenacemideThe risk or severity of adverse effects can be increased when Phenacemide is combined with Vancomycin.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Vancomycin.Experimental
PhencyclidineThe risk or severity of adverse effects can be increased when Phencyclidine is combined with Vancomycin.Illicit
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Vancomycin.Approved
PhenethylamineThe risk or severity of adverse effects can be increased when Phenethylamine is combined with Vancomycin.Experimental
PheneturideThe risk or severity of adverse effects can be increased when Pheneturide is combined with Vancomycin.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with Vancomycin.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Vancomycin.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Vancomycin.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Vancomycin.Experimental
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Vancomycin.Withdrawn
PhenprobamateThe risk or severity of adverse effects can be increased when Phenprobamate is combined with Vancomycin.Experimental
PhensuximideThe risk or severity of adverse effects can be increased when Phensuximide is combined with Vancomycin.Approved
PhentermineThe risk or severity of adverse effects can be increased when Vancomycin is combined with Phentermine.Approved, Illicit
PhenylbutazonePhenylbutazone may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Vet Approved
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Vancomycin.Approved, Vet Approved
PiclozotanThe risk or severity of adverse effects can be increased when Vancomycin is combined with Piclozotan.Investigational
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Vancomycin.Approved
PimavanserinThe risk or severity of adverse effects can be increased when Pimavanserin is combined with Vancomycin.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Vancomycin.Approved
PinazepamThe risk or severity of adverse effects can be increased when Pinazepam is combined with Vancomycin.Experimental
PindololThe risk or severity of adverse effects can be increased when Vancomycin is combined with Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Vancomycin.Approved, Investigational
PipecuroniumThe therapeutic efficacy of Pipecuronium can be increased when used in combination with Vancomycin.Approved
PiperacillinPiperacillin may increase the nephrotoxic activities of Vancomycin.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Vancomycin.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Vancomycin.Approved, Investigational
PirlimycinThe risk or severity of adverse effects can be increased when Pirlimycin is combined with Vancomycin.Vet Approved
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Vancomycin.Approved
PiroxicamPiroxicam may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Investigational
PirprofenPirprofen may decrease the excretion rate of Vancomycin which could result in a higher serum level.Experimental
PivagabineThe risk or severity of adverse effects can be increased when Pivagabine is combined with Vancomycin.Investigational
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Vancomycin.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Pizotifen is combined with Vancomycin.Approved
PlazomicinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Plazomicin.Approved, Investigational
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when Vancomycin is combined with Polymyxin B Sulfate.Approved, Vet Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Vancomycin.Approved
PramipexoleVancomycin may increase the sedative activities of Pramipexole.Approved, Investigational
PranoprofenPranoprofen may decrease the excretion rate of Vancomycin which could result in a higher serum level.Experimental, Investigational
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Vancomycin.Approved, Illicit
PregabalinThe therapeutic efficacy of Vancomycin can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PridinolThe risk or severity of adverse effects can be increased when Pridinol is combined with Vancomycin.Experimental
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Vancomycin.Approved, Vet Approved
ProcainamideThe risk or severity of adverse effects can be increased when Procainamide is combined with Vancomycin.Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Vancomycin.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Vancomycin.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Vancomycin.Approved, Vet Approved
ProgabideThe risk or severity of adverse effects can be increased when Progabide is combined with Vancomycin.Approved, Investigational
ProglumetacinProglumetacin may decrease the excretion rate of Vancomycin which could result in a higher serum level.Experimental
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Vancomycin.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Vancomycin.Approved, Investigational
PropacetamolPropacetamol may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with Vancomycin.Experimental
PropericiazineThe risk or severity of adverse effects can be increased when Propericiazine is combined with Vancomycin.Approved, Investigational
PropiomazineThe risk or severity of adverse effects can be increased when Propiomazine is combined with Vancomycin.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Propiopromazine is combined with Vancomycin.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Vancomycin.Approved, Investigational, Vet Approved
PropyphenazonePropyphenazone may decrease the excretion rate of Vancomycin which could result in a higher serum level.Experimental
ProquazoneProquazone may decrease the excretion rate of Vancomycin which could result in a higher serum level.Experimental
ProthipendylThe risk or severity of adverse effects can be increased when Prothipendyl is combined with Vancomycin.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Vancomycin.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with Vancomycin.Experimental
PRX-08066The risk or severity of adverse effects can be increased when Vancomycin is combined with PRX-08066.Investigational
PsilocybineThe risk or severity of adverse effects can be increased when Psilocybine is combined with Vancomycin.Investigational
PuromycinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Puromycin.Experimental
PyrantelThe therapeutic efficacy of Pyrantel can be increased when used in combination with Vancomycin.Approved, Vet Approved
PyrithyldioneThe risk or severity of adverse effects can be increased when Pyrithyldione is combined with Vancomycin.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Vancomycin.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Vancomycin.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Vancomycin.Approved, Investigational
QuinineThe risk or severity of adverse effects can be increased when Quinine is combined with Vancomycin.Approved
QuinupramineThe risk or severity of adverse effects can be increased when Quinupramine is combined with Vancomycin.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with Vancomycin.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Vancomycin.Approved, Investigational
RamosetronThe risk or severity of adverse effects can be increased when Vancomycin is combined with Ramosetron.Approved, Investigational
RapacuroniumThe therapeutic efficacy of Rapacuronium can be increased when used in combination with Vancomycin.Withdrawn
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Vancomycin.Approved
ReboxetineThe risk or severity of adverse effects can be increased when Reboxetine is combined with Vancomycin.Approved, Investigational
RemacemideThe risk or severity of adverse effects can be increased when Remacemide is combined with Vancomycin.Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Vancomycin.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Vancomycin.Approved, Withdrawn
RenzaprideThe risk or severity of adverse effects can be increased when Vancomycin is combined with Renzapride.Investigational
RepinotanThe risk or severity of adverse effects can be increased when Vancomycin is combined with Repinotan.Investigational
ReposalThe risk or severity of adverse effects can be increased when Reposal is combined with Vancomycin.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Vancomycin.Approved, Investigational
RibostamycinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Ribostamycin.Approved, Investigational
RiluzoleThe risk or severity of adverse effects can be increased when Riluzole is combined with Vancomycin.Approved, Investigational
RisedronateThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Vancomycin is combined with Risedronate.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Vancomycin.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Ritanserin.Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Vancomycin is combined with Rizatriptan.Approved
RobenacoxibRobenacoxib may decrease the excretion rate of Vancomycin which could result in a higher serum level.Experimental, Vet Approved
RocuroniumThe therapeutic efficacy of Rocuronium can be increased when used in combination with Vancomycin.Approved
RofecoxibRofecoxib may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Investigational, Withdrawn
RolipramThe risk or severity of adverse effects can be increased when Rolipram is combined with Vancomycin.Investigational
RolitetracyclineThe risk or severity of adverse effects can be increased when Rolitetracycline is combined with Vancomycin.Approved
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Vancomycin.Vet Approved
RopiniroleVancomycin may increase the sedative activities of Ropinirole.Approved, Investigational
RotigotineVancomycin may increase the sedative activities of Rotigotine.Approved
RP-5063The risk or severity of adverse effects can be increased when RP-5063 is combined with Vancomycin.Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Vancomycin.Approved
SafinamideThe risk or severity of adverse effects can be increased when Vancomycin is combined with Safinamide.Approved, Investigational
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Vancomycin.Withdrawn
SalicylamideSalicylamide may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
Salicylic acidSalicylic acid may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
Salmonella typhi Ty21a live antigenThe therapeutic efficacy of Salmonella typhi Ty21a live antigen can be decreased when used in combination with Vancomycin.Approved
SalsalateSalsalate may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
SaredutantThe risk or severity of adverse effects can be increased when Saredutant is combined with Vancomycin.Investigational
SarpogrelateThe risk or severity of adverse effects can be increased when Vancomycin is combined with Sarpogrelate.Investigational
SC-236SC-236 may decrease the excretion rate of Vancomycin which could result in a higher serum level.Experimental, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Vancomycin.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Vancomycin.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Vancomycin.Approved, Investigational, Vet Approved
SerotoninThe risk or severity of adverse effects can be increased when Vancomycin is combined with Serotonin.Investigational, Nutraceutical
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Vancomycin.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Vancomycin is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Vancomycin.Approved, Vet Approved
SibutramineThe risk or severity of adverse effects can be increased when Sibutramine is combined with Vancomycin.Approved, Illicit, Investigational, Withdrawn
SisomicinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Sisomicin.Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Vancomycin.Approved
St. John's WortThe risk or severity of adverse effects can be increased when St. John's Wort is combined with Vancomycin.Approved, Investigational, Nutraceutical
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with Vancomycin.Approved
StreptomycinThe risk or severity of adverse effects can be increased when Streptomycin is combined with Vancomycin.Approved, Vet Approved
StyramateThe risk or severity of adverse effects can be increased when Styramate is combined with Vancomycin.Experimental
SuccinylcholineThe therapeutic efficacy of Succinylcholine can be increased when used in combination with Vancomycin.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Vancomycin.Approved, Investigational
SulfasalazineSulfasalazine may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
SulindacSulindac may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Vancomycin.Approved, Investigational
SulthiameThe risk or severity of adverse effects can be increased when Sulthiame is combined with Vancomycin.Experimental
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with Vancomycin.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Vancomycin is combined with Sumatriptan.Approved, Investigational
SuprofenSuprofen may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Withdrawn
SuvorexantVancomycin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
SuxibuzoneSuxibuzone may decrease the excretion rate of Vancomycin which could result in a higher serum level.Experimental
TalbutalThe risk or severity of adverse effects can be increased when Talbutal is combined with Vancomycin.Approved, Illicit
TalniflumateTalniflumate may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
TalopramThe risk or severity of adverse effects can be increased when Talopram is combined with Vancomycin.Experimental
TandospironeThe risk or severity of adverse effects can be increased when Tandospirone is combined with Vancomycin.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Vancomycin.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Vancomycin.Approved, Investigational
TD-8954The risk or severity of adverse effects can be increased when Vancomycin is combined with TD-8954.Investigational
Tedizolid phosphateThe risk or severity of adverse effects can be increased when Vancomycin is combined with Tedizolid phosphate.Approved
TegaserodThe risk or severity of adverse effects can be increased when Vancomycin is combined with Tegaserod.Approved, Investigational, Withdrawn
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Vancomycin.Approved, Investigational
TenidapTenidap may decrease the excretion rate of Vancomycin which could result in a higher serum level.Experimental
TenofovirThe serum concentration of Tenofovir can be increased when it is combined with Vancomycin.Experimental, Investigational
Tenofovir alafenamideThe serum concentration of Tenofovir alafenamide can be increased when it is combined with Vancomycin.Approved
Tenofovir disoproxilThe serum concentration of Tenofovir disoproxil can be increased when it is combined with Vancomycin.Approved, Investigational
TenoxicamTenoxicam may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
TepoxalinTepoxalin may decrease the excretion rate of Vancomycin which could result in a higher serum level.Vet Approved
TetracyclineThe risk or severity of adverse effects can be increased when Tetracycline is combined with Vancomycin.Approved, Vet Approved
TetraethylammoniumThe risk or severity of adverse effects can be increased when Vancomycin is combined with Tetraethylammonium.Experimental, Investigational
TetrahydrocannabivarinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Tetrahydrocannabivarin.Investigational
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Vancomycin.Investigational
TetrazepamThe risk or severity of adverse effects can be increased when Tetrazepam is combined with Vancomycin.Experimental
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Vancomycin.Investigational
ThalidomideVancomycin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Vancomycin.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when Thiazinam is combined with Vancomycin.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Vancomycin.Withdrawn
ThiocolchicosideThe risk or severity of adverse effects can be increased when Thiocolchicoside is combined with Vancomycin.Approved, Investigational
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Vancomycin.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Thiopropazate is combined with Vancomycin.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Thioproperazine is combined with Vancomycin.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Vancomycin.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Vancomycin.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Vancomycin.Approved, Investigational
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Vancomycin.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with Vancomycin.Approved, Investigational
Tiaprofenic acidTiaprofenic acid may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
TigecyclineThe risk or severity of adverse effects can be increased when Tigecycline is combined with Vancomycin.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Vancomycin.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Vancomycin.Experimental
Tiludronic acidThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Vancomycin is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TinoridineTinoridine may decrease the excretion rate of Vancomycin which could result in a higher serum level.Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Vancomycin.Approved, Investigational
TobramycinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Tobramycin.Approved, Investigational
TofisopamThe risk or severity of adverse effects can be increased when Tofisopam is combined with Vancomycin.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Vancomycin.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Investigational
TolmetinTolmetin may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Vancomycin.Approved
TolperisoneThe risk or severity of adverse effects can be increased when Tolperisone is combined with Vancomycin.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Vancomycin.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Vancomycin.Approved, Investigational
TramiprosateThe risk or severity of adverse effects can be increased when Tramiprosate is combined with Vancomycin.Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Vancomycin.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Vancomycin is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Vancomycin.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with Vancomycin.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with Vancomycin.Approved
TriclofosThe risk or severity of adverse effects can be increased when Triclofos is combined with Vancomycin.Withdrawn
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Vancomycin.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with Vancomycin.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Vancomycin.Approved, Vet Approved
TrimethadioneThe risk or severity of adverse effects can be increased when Trimethadione is combined with Vancomycin.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Vancomycin is combined with Trimethaphan.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Vancomycin.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Vancomycin.Approved
Trolamine salicylateTrolamine salicylate may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved
TropisetronThe risk or severity of adverse effects can be increased when Vancomycin is combined with Tropisetron.Approved, Investigational
TubocurarineThe risk or severity of adverse effects can be increased when Vancomycin is combined with Tubocurarine.Approved
UrapidilThe risk or severity of adverse effects can be increased when Vancomycin is combined with Urapidil.Investigational
VabicaserinThe risk or severity of adverse effects can be increased when Vancomycin is combined with Vabicaserin.Investigational
ValdecoxibValdecoxib may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Investigational, Withdrawn
ValerianThe risk or severity of adverse effects can be increased when Valerian is combined with Vancomycin.Approved, Experimental, Investigational
ValnoctamideThe risk or severity of adverse effects can be increased when Valnoctamide is combined with Vancomycin.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Vancomycin.Approved, Investigational
ValpromideThe risk or severity of adverse effects can be increased when Valpromide is combined with Vancomycin.Experimental
VecuroniumThe therapeutic efficacy of Vecuronium can be increased when used in combination with Vancomycin.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Vancomycin is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with Vancomycin.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Vancomycin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Vancomycin.Approved
ViloxazineThe risk or severity of adverse effects can be increased when Viloxazine is combined with Vancomycin.Approved, Investigational, Withdrawn
VinbarbitalThe risk or severity of adverse effects can be increased when Vinbarbital is combined with Vancomycin.Experimental
VinpocetineThe risk or severity of adverse effects can be increased when Vinpocetine is combined with Vancomycin.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with Vancomycin.Experimental
VinylbitalThe risk or severity of adverse effects can be increased when Vinylbital is combined with Vancomycin.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Vancomycin.Approved, Investigational
WortmanninThe risk or severity of adverse effects can be increased when Vancomycin is combined with Wortmannin.Experimental
XP19986The risk or severity of adverse effects can be increased when XP19986 is combined with Vancomycin.Investigational
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Vancomycin.Vet Approved
YKP-1358The risk or severity of adverse effects can be increased when Vancomycin is combined with YKP-1358.Investigational
YohimbineThe risk or severity of adverse effects can be increased when Vancomycin is combined with Yohimbine.Approved, Investigational, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Vancomycin.Approved, Illicit, Investigational
ZaltoprofenZaltoprofen may decrease the excretion rate of Vancomycin which could result in a higher serum level.Approved, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with Vancomycin.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Vancomycin is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Vancomycin.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Vancomycin.Vet Approved
Zoledronic acidThe risk or severity of nephrotoxicity and hypocalcemia can be increased when Vancomycin is combined with Zoledronic acid.Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Vancomycin is combined with Zolmitriptan.Approved, Investigational
ZolpidemVancomycin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZomepiracZomepirac may decrease the excretion rate of Vancomycin which could result in a higher serum level.Withdrawn
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Vancomycin.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Vancomycin.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Vancomycin.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Vancomycin.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Boger DL. Vancomycin, teicoplanin, and ramoplanin: synthetic and mechanistic studies. Med Res Rev. 2001 Sep;21(5):356-81. Pubmed

General References
  1. Levine DP: Vancomycin: a history. Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S5-12. [PubMed:16323120]
  2. Small PM, Chambers HF: Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother. 1990 Jun;34(6):1227-31. [PubMed:2393284]
  3. Gonzalez C, Rubio M, Romero-Vivas J, Gonzalez M, Picazo JJ: Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis. 1999 Nov;29(5):1171-7. [PubMed:10524959]
  4. Sivagnanam S, Deleu D: Red man syndrome. Crit Care. 2003 Apr;7(2):119-20. Epub 2002 Dec 23. [PubMed:12720556]
  5. Cantu TG, Yamanaka-Yuen NA, Lietman PS: Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis. 1994 Apr;18(4):533-43. [PubMed:8038306]
  6. Rybak MJ: The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S35-9. doi: 10.1086/491712. [PubMed:16323118]
  7. Butterfield JM, Patel N, Pai MP, Rosano TG, Drusano GL, Lodise TP: Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding. Antimicrob Agents Chemother. 2011 Sep;55(9):4277-82. doi: 10.1128/AAC.01674-10. Epub 2011 Jun 13. [PubMed:21670191]
  8. Matzke GR, Zhanel GG, Guay DR: Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet. 1986 Jul-Aug;11(4):257-82. doi: 10.2165/00003088-198611040-00001. [PubMed:3530582]
  9. CutisPharma Announces FDA Approval of Firvanq (vancomycin) for Treatment of Clostridium Difficile Associated Diarrhea and Staphylococcus Aureus Colitis [Link]
  10. Wikipedia Page on Vancomycin [Link]
External Links
Human Metabolome Database
HMDB0014653
KEGG Drug
D00212
KEGG Compound
C06689
PubChem Compound
14969
PubChem Substance
46505261
ChemSpider
14253
BindingDB
50335519
ChEBI
28001
ChEMBL
CHEMBL262777
Therapeutic Targets Database
DAP001330
PharmGKB
PA451850
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Vancomycin
ATC Codes
A07AA09 — VancomycinJ01XA01 — Vancomycin
AHFS Codes
  • 08:12.28.16 — Glycopeptides
FDA label
Download (57.8 KB)
MSDS
Download (73 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic ScienceBMI >30 kg/m2 / Bone destruction / Diabetes Mellitus (DM) / Inflammatory Reaction1
0CompletedTreatmentBacterial Resistance / Respiratory Failure / Respiratory Tract Infections (RTI)1
0Enrolling by InvitationBasic ScienceDietary Modifications / Nutrition1
0RecruitingTreatmentEarly Stage Non-small Cell Lung Cancer1
1CompletedBasic ScienceSimvastatin Pharmacokinetics and Gut Microbiome1
1CompletedSupportive CareCritical Illness / Methicillin-Resistant Staphylococcus Aureus (MRSA) / Sepsis1
1CompletedTreatmentBiliary Atresia / Primary Sclerosing Cholangitis (PSC)1
1CompletedTreatmentCystic Fibrosis (CF) / Healthy Volunteers1
1CompletedTreatmentPrimary Sclerosing Cholangitis (PSC)1
1RecruitingTreatmentBiliary Atresia / Primary Sclerosing Cholangitis (PSC)1
1RecruitingTreatmentClostridium Difficile Infection (CDI)1
1RecruitingTreatmentDialysis therapy / Pediatric Continuous Renal Replacement Therapy / Renal Failure1
1TerminatedPreventionSurgical Site Infections1
1Unknown StatusTreatmentCystic Fibrosis (CF) / Methicillin-Resistant Staphylococcus Aureus (MRSA)1
1WithdrawnPreventionNeurosurgery1
1, 2CompletedTreatmentAutism Spectrum Conditions/Disorders / Gastrointestinal Problems1
1, 2Not Yet RecruitingPreventionElective Craniotomy-candidated Patients1
2Active Not RecruitingTreatmentChronic Constipation / Slow Transit Constipation1
2CompletedTreatmentBacteremia1
2CompletedTreatmentBacterial Infections1
2CompletedTreatmentBacterial Infections / Infection NOS1
2CompletedTreatmentClostridium Difficile Infection (CDI)2
2CompletedTreatmentClostridium Difficile Infection (CDI) / Diarrhea1
2CompletedTreatmentClostridium Difficile / Pseudomembranous Colitis1
2CompletedTreatmentModerate Clostridium Difficile Infection1
2CompletedTreatmentOsteomyelitis1
2CompletedTreatmentRecurrent C. Difficile Infection1
2CompletedTreatmentSkin and Subcutaneous Tissue Bacterial Infections1
2CompletedTreatmentSoft Tissues Infections1
2CompletedTreatmentStaphylococcal Skin Infections1
2Enrolling by InvitationPreventionInfection NOS1
2Not Yet RecruitingTreatmentClostridium difficile infection recurrence1
2Not Yet RecruitingTreatmentCrohn's Disease (CD)1
2Not Yet RecruitingTreatmentEnd Stage Renal Disease (ESRD)1
2RecruitingPreventionClostridium Difficile Infection (CDI) / Clostridium difficile infection recurrence1
2RecruitingTreatmentAutism Spectrum Conditions/Disorders / Gastrointestinal Disorders1
2RecruitingTreatmentClostridium Difficile1
2RecruitingTreatmentCrohn's Disease (CD)1
2RecruitingTreatmentLate Onset Neonatal Sepsis1
2RecruitingTreatmentMethicillin-Resistant Staphylococcus Aureus (MRSA) / Pneumonia, Staphylococcal1
2RecruitingTreatmentPre-Diabetic1
2TerminatedTreatmentBacteremia Due to Staphylococcus Aureus1
2TerminatedTreatmentEndocarditis, Bacterial / Infective Endocarditis1
2TerminatedTreatmentHealth-Care-Associated Pneumonia / Pneumonia, Hospital-Acquired / Ventilator-Associated Pneumonia (VAP)1
2TerminatedTreatmentInfected Spacers / Prosthetic Joint Infections of Hip / Prosthetic Joint Infections of Knee1
2TerminatedTreatmentNeoplasms / Neutropenia, Febrile1
2TerminatedTreatmentOsteomyelitis1
2Unknown StatusPreventionWound Infections1
2Unknown StatusTreatmentHip Prosthetic Joint Infection1
2, 3CompletedTreatmentArthropathy of Knee Joint / Revision, Knee Joint1
2, 3Not Yet RecruitingPreventionArthropathy of Knee Joint1
2, 3Not Yet RecruitingTreatmentClostridium Difficile Infection (CDI)1
2, 3RecruitingTreatmentClostridium Difficile1
2, 3TerminatedTreatmentClostridium Difficile Infection (CDI)1
2, 3TerminatedTreatmentClostridium difficile infection recurrence / Laboratory Confirmed Clostridium Difficile Infection1
3Active Not RecruitingTreatmentBacteremia1
3Active Not RecruitingTreatmentPrimary Sclerosing Cholangitis (PSC)1
3CompletedSupportive CareBone Marrow Suppression / Fever, Sweats, and Hot Flashes / Infection NOS / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Unspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific1
3CompletedTreatmentAbscesses / Cellulitis / Surgical Site Infections / Wound Infections2
3CompletedTreatmentAbscesses / Cellulitis / Systemic Inflammation / Wound Infections2
3CompletedTreatmentAcute Hematogenous Osteomyelitis1
3CompletedTreatmentBacteremia / Bacterial Infections / Infections, Gram-Positive Bacterial1
3CompletedTreatmentBacterial Infections1
3CompletedTreatmentClostridium Difficile1
3CompletedTreatmentClostridium Difficile Infection (CDI)4
3CompletedTreatmentClostridium Difficile-Associated Diarrhea (CDAD)1
3CompletedTreatmentClostridium Infections / Diarrhea2
3CompletedTreatmentComplicated Skin and Soft Tissue Infection1
3CompletedTreatmentInfection caused by staphylococci1
3CompletedTreatmentInfection caused by staphylococci / Meningitis / Pneumonia / Sepsis1
3CompletedTreatmentInfectious / Skin Diseases1
3CompletedTreatmentNeutropenia, Febrile1
3CompletedTreatmentNosocomial Neonatal Sepsis1
3CompletedTreatmentPneumonia, Bacterial2
3CompletedTreatmentSkin Diseases, Bacterial / Skin Diseases, Infectious / Staphylococcal Skin Infections1
3CompletedTreatmentSkin Structures and Soft Tissue Infections2
3CompletedTreatmentSkin and Subcutaneous Tissue Bacterial Infections / Skin Structures and Soft Tissue Infections1
3CompletedTreatmentSkin and Subcutaneous Tissue Bacterial Infections1
3CompletedTreatmentStaphylococcal Skin Infections2
3Not Yet RecruitingTreatmentCataract operation / Endophthalmitis / Intracameral Antibiotics / Moxifloxacin / Phacoemulsification / Vancomycin1
3Not Yet RecruitingTreatmentChronic Rhinosinusitis (Diagnosis)1
3Not Yet RecruitingTreatmentClostridium Difficile1
3Not Yet RecruitingTreatmentClostridium Difficile Infection (CDI)2
3RecruitingPreventionGeneral Surgery / Infection NOS / Nervous System Diseases1
3RecruitingTreatmentClostridium Difficile1
3RecruitingTreatmentClostridium Difficile Infection (CDI)1
3RecruitingTreatmentConjunctivitis, Bacterial1
3RecruitingTreatmentSkin Diseases, Bacterial / Skin Diseases, Infectious1
3RecruitingTreatmentStaphylococcus Aureus Infections1
3TerminatedTreatmentBacteremia / Infections, Gram-Positive Bacterial1
3TerminatedTreatmentClostridium Infections1
3TerminatedTreatmentComplicated Skin and Soft Tissue Infection1
3TerminatedTreatmentDiabetic Foot1
3TerminatedTreatmentSkin Diseases, Infectious / Soft Tissues Infections1
4Active Not RecruitingBasic ScienceInflammatory Bowel Diseases (IBD) / Primary Sclerosing Cholangitis (PSC)1
4Active Not RecruitingPreventionArrythmias1
4Active Not RecruitingPreventionCalcium Nephrolithiasis / Urinary Tract Infections (UTIs)1
4CompletedNot AvailableComplicated Skin and Structure Infection / Hospital-acquired bacterial pneumonia1
4CompletedNot AvailableStaphylococcus Aureus1
4CompletedBasic ScienceCellulitis1
4CompletedPreventionAortic Valve Disorder / Congenital Heart Disease (CHD)1
4CompletedPreventionClostridium Difficile Infection (CDI) / Prophylaxis / Vancomycin1
4CompletedPreventionMRSA Infections1
4CompletedTreatmentBacteremia1
4CompletedTreatmentCellulitis1
4CompletedTreatmentCellulitis / Skin-structure infections1
4CompletedTreatmentClostridium Difficile1
4CompletedTreatmentCoronary Artery Disease1
4CompletedTreatmentExtracorporeal Membrane Oxygenation1
4CompletedTreatmentInfection NOS / Neutropenia, Febrile1
4CompletedTreatmentInfection NOS / Pneumonia1
4CompletedTreatmentInfective Endocarditis1
4CompletedTreatmentMethicillin Resistant Staphylococcus Aureus (MRSA)1
4CompletedTreatmentMethicillin Resistant Staphylococcus Aureus (MRSA) / Skin/Soft Tissue Infections1
4CompletedTreatmentSkin Diseases, Infectious / Staphylococcal Skin Infections1
4CompletedTreatmentStaphylococcal Skin Infections1
4CompletedTreatmentSurgical Site Infections / Vancomycin1
4CompletedTreatmentVentilator-Associated Pneumonia (VAP)1
4Enrolling by InvitationOtherClostridium Difficile Infection (CDI) / Diarrhea1
4Enrolling by InvitationPreventionClostridium Difficile Infection (CDI)1
4Enrolling by InvitationPreventionFractures, Open / Infection, Postoperative Wound1
4Enrolling by InvitationTreatmentVancomycin1
4Not Yet RecruitingBasic ScienceMicrobial Colonization1
4Not Yet RecruitingPreventionCarpal Tunnel Syndrome (CTS)1
4Not Yet RecruitingPreventionSurgical Site Infections1
4Not Yet RecruitingTreatmentClostridium Difficile Infection (CDI)1
4Not Yet RecruitingTreatmentFevers / Neutropenia, Febrile1
4RecruitingBasic ScienceNeonatal Infections1
4RecruitingBasic ScienceRabies Human1
4RecruitingPreventionClostridium Difficile Infection (CDI)2
4RecruitingPreventionSpinal Fusion Acquired1
4RecruitingPreventionSurgical Site Infections2
4RecruitingTreatmentAsthma Bronchial1
4RecruitingTreatmentBlood Stream Infections / Endocarditis / MRSA1
4RecruitingTreatmentBone Infection / Joint Infections / Osteomyelitis / Prosthetic Joint Infection / Septic Arthritis1
4RecruitingTreatmentClostridium Difficile Infection (CDI)1
4RecruitingTreatmentClostridium / Difficile / Fidaxomicin / Vancomycin1
4RecruitingTreatmentPrimary Sclerosing Cholangitis (PSC)1
4TerminatedNot AvailableBacteremia / Pneumonia1
4TerminatedHealth Services ResearchComplicated Skin or Skin Structure Infection1
4TerminatedPreventionAcute acute bacterial skin and skin structure infections / Bacteremia / Endocarditis / Health Care Associated Pneumonia / Osteomyelitis/Septic Arthritis1
4TerminatedPreventionInfection caused by staphylococci / Methicillin-Resistant Staphylococcus Aureus (MRSA)1
4TerminatedTreatmentBacteremia1
4TerminatedTreatmentClostridium Difficile1
4TerminatedTreatmentClostridium Difficile / Spinal Cord Injuries (SCI)1
4TerminatedTreatmentDiabetic Foot1
4TerminatedTreatmentImpaired Renal Function / S. Aureus Bacteremia / Skin and Subcutaneous Tissue Bacterial Infections1
4Unknown StatusPreventionClostridium Difficile Infection (CDI)1
4Unknown StatusTreatmentClostridium Difficile Infection (CDI)1
4Unknown StatusTreatmentLiver Cirrhosis1
Not AvailableActive Not RecruitingTreatmentClostridium Difficile Infection (CDI)1
Not AvailableCompletedNot AvailableAcinetobacter Infections1
Not AvailableCompletedNot AvailableAllogenic Blood Stem Cell Transplantation / Neutropenia, Febrile1
Not AvailableCompletedNot AvailableC. Difficile / Diarrhea / Enterocolitis1
Not AvailableCompletedNot AvailableEnd Stage Renal Disease (ESRD) / Infection NOS1
Not AvailableCompletedNot AvailableMethicillin-Resistant Staphylococcus Aureus (MRSA) / Pneumonia, Hospital-Acquired1
Not AvailableCompletedNot AvailableOsteomyelitis1
Not AvailableCompletedNot AvailablePeriodontal Diseases / Psoriatic Arthritis / Rheumatoid Arthritis1
Not AvailableCompletedNot AvailablePneumonia1
Not AvailableCompletedBasic ScienceEndotoxaemia1
Not AvailableCompletedBasic ScienceHealthy Volunteers / Sepsis1
Not AvailableCompletedOtherFlu caused by Influenza1
Not AvailableCompletedPreventionDental Decay1
Not AvailableCompletedPreventionProsthetic Joint Infection1
Not AvailableCompletedTreatmentAntibiotic Prophylaxis1
Not AvailableCompletedTreatmentClostridium Difficile Infection (CDI)1
Not AvailableCompletedTreatmentInfection caused by staphylococci1
Not AvailableCompletedTreatmentInfectious Diseases1
Not AvailableCompletedTreatmentPeritoneal Dialysis Associated Peritonitis1
Not AvailableCompletedTreatmentSkin and Soft Tissue Infections1
Not AvailableCompletedTreatmentUlcerative Colitis (UC)1
Not AvailableEnrolling by InvitationPreventionFractures, Closed / Infection NOS1
Not AvailableNot Yet RecruitingNot AvailableAcute Kidney Injury (AKI) / Adverse Effects / Cross-Sectional Study / Infection caused by staphylococci / Vancomycin1
Not AvailableNot Yet RecruitingNot AvailableAcute Kidney Insufficiency / Anti-Infective Agent Toxicity1
Not AvailableRecruitingNot AvailableCritical Illness / Infection NOS1
Not AvailableRecruitingPreventionAntibiotic Prophylaxis / Thoracic Surgery1
Not AvailableRecruitingPreventionPost- Orthotopic Liver Transplantation / Primary Sclerosing Cholangitis (PSC)1
Not AvailableRecruitingPreventionSurgical Site Infections1
Not AvailableRecruitingTreatmentBMI >30 kg/m2 / Infection NOS / Sepsis1
Not AvailableTerminatedTreatmentColitis1
Not AvailableTerminatedTreatmentInfection NOS2
Not AvailableUnknown StatusBasic ScienceBMI >30 kg/m2 / Insulin Resistance1
Not AvailableUnknown StatusPreventionInfection NOS1
Not AvailableUnknown StatusPreventionLow Back Pain (LBP)1
Not AvailableUnknown StatusTreatmentAcute Renal Failure (ARF) / Postoperative / Sepsis1
Not AvailableUnknown StatusTreatmentClostridium Difficile / Clostridium Difficile Infection (CDI)1
Not AvailableUnknown StatusTreatmentInfection NOS1
Not AvailableUnknown StatusTreatmentInfection, Postoperative Wound1
Not AvailableUnknown StatusTreatmentMethicillin-Resistant Staphylococcus Aureus (MRSA) / Osteomyelitis1
Not AvailableWithdrawnSupportive CareInfection NOS / Neutropenias / Unspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific1

Pharmacoeconomics

Manufacturers
  • Viropharma inc
  • Lederle parenterals inc
  • Baxter healthcare corp
  • Baxter healthcare corp anesthesia and critical care
  • Akorn strides llc
  • App pharmaceuticals llc
  • Bioniche pharma usa llc
  • Hospira inc
  • Sandoz inc
  • Pharmacia and upjohn co
Packagers
  • ACS Dobfar SPA
  • Akorn Inc.
  • Amerisource Health Services Corp.
  • APP Pharmaceuticals
  • Baxter International Inc.
  • Cardinal Health
  • General Injectables and Vaccines Inc.
  • Generamedix Inc.
  • Hospira Inc.
  • Medisca Inc.
  • Mustafa Nevzat Ilac Sanayii AS
  • Neuman Distributors Inc.
  • Norwich Pharmaceuticals Inc.
  • Pharmedium
  • Sandoz
  • Strides Arcolab Limited
  • Viropharma Inc.
Dosage forms
FormRouteStrength
KitOral
CapsuleOral125 mg
CapsuleOral250 mg
Powder, for solutionIntravenous1.0 g
Injection, powder, lyophilized, for solutionIntravenous1 g/20mL
Injection, powder, lyophilized, for solutionIntravenous500 mg/10mL
PowderIntravenous1 g
Injection, powder, lyophilized, for solutionIntravenous10 g/100mL
Injection, solutionIntravenous4.2 mg/mL
Injection, solutionIntravenous5 mg/mL
Injection, solutionIntravenous6 mg/mL
CapsuleOral125 mg/1
CapsuleOral250 mg/1
InjectionIntravenous10 g/100mL
InjectionIntravenous5 g/100mL
Injection, powder, lyophilized, for solutionIntravenous1 g/8mL
Injection, powder, lyophilized, for solutionIntravenous1 g/250mL
Injection, powder, lyophilized, for solutionIntravenous1 g/1
Injection, powder, lyophilized, for solutionIntravenous1.25 g/25mL
Injection, powder, lyophilized, for solutionIntravenous1.5 g/30mL
Injection, powder, lyophilized, for solutionIntravenous10 g/1
Injection, powder, lyophilized, for solutionIntravenous100 g/1
Injection, powder, lyophilized, for solutionIntravenous100 mg/mL
Injection, powder, lyophilized, for solutionIntravenous250 mg/5mL
Injection, powder, lyophilized, for solutionIntravenous5 g/1
Injection, powder, lyophilized, for solutionIntravenous5 g/100mL
Injection, powder, lyophilized, for solutionIntravenous500 mg/100mL
Injection, powder, lyophilized, for solutionIntravenous500 mg/1
Injection, powder, lyophilized, for solutionIntravenous500 mg/4mL
Injection, powder, lyophilized, for solutionIntravenous750 mg/1
Injection, powder, lyophilized, for solutionIntravenous750 mg/15mL
Injection, solutionIntravenous1 g/1
Injection, solutionIntravenous1 g/200mL
Injection, solutionIntravenous500 mg/100mL
Injection, solutionIntravenous500 mg/1
Injection, solutionIntravenous750 mg/150mL
Powder, for solutionIntravenous10 g
Powder, for solutionIntravenous1000 mg
Powder, for solutionIntravenous1 g
Powder, for solutionIntravenous5 g
Powder, for solutionIntravenous500 mg
Injection, powder, lyophilized, for solutionIntravenous10 g/80mL
Prices
Unit descriptionCostUnit
Vancocin HCl 20 250 mg capsule Box1019.87USD box
Vancomycin hcl powder85.68USD g
Pms-Vancomycin 1 g/vial61.98USD vial
Vancocin hcl 250 mg pulvule40.97USD each
Pms-Vancomycin 500 mg/vial32.62USD vial
Vancocin HCl 125 mg capsule27.66USD capsule
Vancocin hcl 125 mg pulvule22.22USD each
Vancomycin 1 gm vial7.0USD vial
Vancomycin hcl 750 mg vial5.72USD vial
Vancomycin 500 mg vial3.74USD vial
Vancomycin-ns 1.5 g/150 ml0.24USD ml
Vancomycin-ns 1.25 g/150 ml0.21USD ml
Vancomycin hcl 1 g/200 ml bag0.17USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
logP-3.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.225 mg/mLALOGPS
logP1.11ALOGPS
logP-4.4ChemAxon
logS-3.8ALOGPS
pKa (Strongest Acidic)2.99ChemAxon
pKa (Strongest Basic)9.93ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count24ChemAxon
Hydrogen Donor Count19ChemAxon
Polar Surface Area530.49 Å2ChemAxon
Rotatable Bond Count13ChemAxon
Refractivity346.61 m3·mol-1ChemAxon
Polarizability138.7 Å3ChemAxon
Number of Rings10ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.7876
Blood Brain Barrier-0.991
Caco-2 permeable-0.7094
P-glycoprotein substrateSubstrate0.8562
P-glycoprotein inhibitor INon-inhibitor0.8781
P-glycoprotein inhibitor IINon-inhibitor0.9636
Renal organic cation transporterNon-inhibitor0.9503
CYP450 2C9 substrateNon-substrate0.8535
CYP450 2D6 substrateNon-substrate0.8323
CYP450 3A4 substrateSubstrate0.6686
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7268
Ames testNon AMES toxic0.5927
CarcinogenicityNon-carcinogens0.8826
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5856 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9987
hERG inhibition (predictor II)Non-inhibitor0.8098
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - DI-ESI-Ion Trap , PositiveLC-MS/MSNot Available
MS/MS Spectrum - DI-ESI-Hybrid FT , PositiveLC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as cyclic peptides. These are compounds containing a cyclic moiety bearing a peptide backbone.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Cyclic peptides
Alternative Parents
Aminoglycosides / Phenolic glycosides / Diarylethers / Disaccharides / O-glycosyl compounds / Alpha amino acids and derivatives / 1-hydroxy-2-unsubstituted benzenoids / 1-hydroxy-4-unsubstituted benzenoids / Aryl chlorides / Oxanes
show 19 more
Substituents
Aminoglycoside core / Cyclic alpha peptide / Phenolic glycoside / O-glycosyl compound / Glycosyl compound / Disaccharide / Diaryl ether / Alpha-amino acid or derivatives / 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid
show 40 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
glycopeptide (CHEBI:28001)

Targets

1. D-Ala-D-Ala moiety of NAM/NAG peptide subunits of peptidoglycan
Kind
Group
Organism
Gram-positive bacteria
Pharmacological action
Yes
Actions
Ligand
References
  1. Reynolds PE: Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur J Clin Microbiol Infect Dis. 1989 Nov;8(11):943-50. [PubMed:2532132]
  2. Reynolds PE, Somner EA: Comparison of the target sites and mechanisms of action of glycopeptide and lipoglycodepsipeptide antibiotics. Drugs Exp Clin Res. 1990;16(8):385-9. [PubMed:2151441]
  3. Boger DL: Vancomycin, teicoplanin, and ramoplanin: synthetic and mechanistic studies. Med Res Rev. 2001 Sep;21(5):356-81. [PubMed:11579438]

Carriers

Details
1. Serum albumin
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Baneres-Roquet F, Gualtieri M, Villain-Guillot P, Pugniere M, Leonetti JP: Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions. Antimicrob Agents Chemother. 2009 Apr;53(4):1528-31. doi: 10.1128/AAC.00971-08. Epub 2009 Jan 21. [PubMed:19164148]
Kind
Protein group
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...

Components:
References
  1. Baneres-Roquet F, Gualtieri M, Villain-Guillot P, Pugniere M, Leonetti JP: Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions. Antimicrob Agents Chemother. 2009 Apr;53(4):1528-31. doi: 10.1128/AAC.00971-08. Epub 2009 Jan 21. [PubMed:19164148]
3. Gamma Globulin
Kind
Protein group
Organism
Human
Pharmacological action
No
Actions
Substrate
References
  1. Baneres-Roquet F, Gualtieri M, Villain-Guillot P, Pugniere M, Leonetti JP: Use of a surface plasmon resonance method to investigate antibiotic and plasma protein interactions. Antimicrob Agents Chemother. 2009 Apr;53(4):1528-31. doi: 10.1128/AAC.00971-08. Epub 2009 Jan 21. [PubMed:19164148]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:41